Firefly Bio

SOUTH SAN FRANCISCO, CA · Founded 2022 · Biotech · Acquired

Degrader-antibody conjugate platform that combines targeted protein degradation with antibody-drug conjugate technology

Claim this profile

Follows are private to you and power your alerts

Updated · fireflybio.com

Sector
Biotech
Headquarters
SOUTH SAN FRANCISCO, CA
Founded
2022
Latest Form D
$40M, Mar 2024
Total capital
$40M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$40M
1 Form D · last Mar 2024
31 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
16 pending

Capital timeline

2024FEDERAL ↑EQUITY ↓Cumulative $40M1st Form D$40M
2024FEDERAL ↑EQUITY ↓Cumulative $40M1st Form D$40M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$40M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Alexander MaywegDirectorNamed in SEC Form D filings
  • Bernhard GeierstangerExecutive OfficerNamed in SEC Form D filings
  • Jerel DavisDirectorNamed in SEC Form D filings
  • John FlygareExecutive OfficerNamed in SEC Form D filings
  • Pankaj BhargavaDirectorNamed in SEC Form D filings
  • Peter ColabuonoDirectorNamed in SEC Form D filings
Show all 8 people
  • Scott HirschExecutive Officer, DirectorNamed in SEC Form D filings
  • Todd FoleyDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 16
  • PendingGlucocorticoid Receptor Agonists And Conjugates ThereofUSPTOApplication 18356148
  • PendingPhenyl Maleimide Linker AgentsUSPTOApplication 18182251
  • PendingDegrader Antibody Conjugates And Uses ThereofUSPTOApplication PCTUS2025035632
Show all 16 patent records
  • Glucocorticoid Receptor Agonists And Conjugates ThereofJul 4, 2024 · Application 18356148Pending
  • Phenyl Maleimide Linker AgentsFeb 29, 2024 · Application 18182251Pending
  • Degrader Antibody Conjugates And Uses ThereofApplication PCTUS2025035632Pending
  • Antibody Conjugates And Uses ThereofApplication 63696072Pending
  • Degrader Antibody Conjugates And Uses ThereofApplication 63665421Pending
  • Isoindolinone-glutarimide Antibody Conjugates, And Uses ThereofApplication PCTUS2024029822Pending
  • Isoindolinone-glutarimide Antibody Conjugates, And Uses ThereofApplication 63557080Pending
  • Glucocorticoid Receptor Agonists And Conjugates ThereofApplication PCTUS2023028287Pending
  • Isoindolinone-glutarimide Antibody Conjugates, And Uses ThereofApplication 63467543Pending
  • Phenyl Maleimide Linker AgentsApplication PCTUS2023064187Pending
  • Glucocorticoid Receptor Agonists And Conjugates ThereofApplication 63489700Pending
  • Phenyl Maleimide Linker AgentsApplication 63391210Pending
  • Glucocorticoid Receptor Agonists And Conjugates ThereofApplication 63368989Pending
  • Isoindolinone-glutarimide Antibody Conjugates, And Uses ThereofApplication 19483678Pending
  • Phenyl Maleimide Linker AgentsApplication 63319197Pending
  • Bcl-xl Degrader Antibody Conjugates And Uses ThereofApplication PCTUS2025035633Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .